Annual Meeting

Biochemist chases the role
of retinoids in fat burning

Gelareh (Abulwerdi)  Vinueza
March 1, 2019

Igor ShmarakovIgor Shmarakov and his mentor published four papers together when their labs were half a world apart.When Igor Shmarakov first learned about retinoids, he had no idea his research interest would send him on a journey back and forth across the globe.

Shmarakov was born and raised in Ukraine. While working on his Ph.D. in biochemistry at Chernivtsi National University, he studied the role of retinoids, natural and synthetic derivatives of retinol, or vitamin A, in inhibiting tumor growth in rat models. After earning his degree, he was appointed an associate professor in the university’s department of biochemistry and biotechnology.

In 2008, Shmarakov received a one-year Fulbright scholarship to do a collaborative research study and was matched with William S. Blaner, a professor of nutritional medicine at the Columbia University College of Physicians and Surgeons, thus beginning a fruitful academic relationship.

Shmarakov returned to Ukraine when his fellowship ended, but he was determined to come back to the U.S. to pursue his dream of becoming an independent researcher. He had a lab at Chernivtsi and supervised graduate students, Shmarakov said, “but at the same time, I continued doing collaborative research studies with Dr. Blaner.”

The long-distance partnership was a challenge, but the two published four papers together between 2009 and 2016. In 2016, Shmarakov applied for an associate research scientist position at Columbia, where he now works under Blaner’s mentorship.

“(The) transition from the Ukrainian academic system into the American academic system was the biggest challenge for me,” Shmarakov said. “Dr. Blaner was very supportive. I owe him. … He kept me scientifically active, and that’s how I was able to come back to the U.S.”

The Journal of Lipid Research has invited Shmarakov to talk about his work in the field of metabolic disease at the 2019 American Society for Biochemistry and Molecular Biology annual meeting.

Role of RBP4 in metabolic disorders

Nonalcoholic fatty liver disease is a metabolic disorder caused by accumulation of fat in the liver. Scientists originally thought the sole function of retinol binding protein 4, or RBP4, was to transport retinol to extrahepatic tissues in times of dietary insufficiency. It is now proposed that adipose-derived RBP4 contributes to the pathogenesis of type 2 diabetes, linking type 2 diabetes with obesity and other obesity-related metabolic diseases.

RBP4 is expressed in both white and brown adipose tissue. The latter, called BAT, contains a large number of mitochondrial uncoupling proteins, allowing them to dissipate thermal energy rather than synthesize ATP. Therefore, metabolically active BAT has therapeutic potential in metabolic disorders.

To study the role of adipocyte-derived RBP4 in metabolic disease, Igor Shmarakov uses several transgenic mouse models, including one that overexpresses human RBP4 in both white and brown adipocytes. When fed a high-fat diet, these adi-hRBP4 mice develop nonalcoholic fatty liver disease, obesity and insulin resistance more readily than matched wild-type mice. Shmarakov’s recent work explores the biochemical cause of this higher weight gain in the adi-hRBP4 mice. The further increase in RBP4 expression in the adi-hRBP4 mice involves a decrease in mitochondrial numbers. Shmarakov proposes that this accounts partially for the excessive weight gain in the adi-hRBP4 mice.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Gelareh (Abulwerdi)  Vinueza

Gelareh (Abulwerdi) Vinueza graduated with her Ph.D. from the molecular medicine program at the University of Maryland, Baltimore. She is currently a policy fellow at the Food and Drug Administration. She has been an ASBMB volunteer writer since 2018 and is passionate about science communication and science policy. Outside of work, she enjoys photography, hiking and cooking.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

‘We're all a bunch of weirdos doing our stuff’
Jobs

‘We're all a bunch of weirdos doing our stuff’

May 20, 2022

An interview with Charles Sanders, a research associate at XBiotech.

Meet the 2022 ASBMB Advocacy Training Program delegates
Announcement

Meet the 2022 ASBMB Advocacy Training Program delegates

May 19, 2022

The fourth cohort of the ASBMB ATP will learn how to advocate for science policy this summer.

Good fellows
Editor's Note

Good fellows

May 18, 2022

“To be a fellow, a member must be generous with time and talent — not just someone whose CV includes pages of individual BMB achievements.”

ASPET announces new leadership
Member News

ASPET announces new leadership

May 16, 2022

Bumpus, Ding, Boise and Linder to assume duties this summer.

James Bryant Howard (1942 – 2022)
Retrospective

James Bryant Howard (1942 – 2022)

May 16, 2022

He was an ASBMB member for more than 40 years, and he served on the Journal of Biological Chemistry editorial board from 1986 to 1991.

A journey with scientists
Essay

A journey with scientists

May 11, 2022

“As I started my career, my first-choice journal was JBC, and my go-to meeting was the ASBMB annual meeting, where I met colleagues and made friends that remain in my life to this day.”